UK’s Early Value Assessment Pilot Is ‘Catalyst’ For Wider Change - NICE
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.
You may also be interested in...
Digital health technologies are evolving rapidly, but UK regulation is lagging behind. Using international standards “as default” could go some way to closing this gap, according to a report by UK medtech trade body ABHI.
An innovative genetic test that can detect which babies are likely to develop deafness if treated with a common antibiotic is set to receive conditional funding in the UK under NICE’s rapid evaluation pilot scheme.
NICE, the body that produces health technology assessment guidance for England and Wales, has earlier this month introduced updates to its evidence standards guidance for developers of digital technologies based on artificial intelligence (AI) and on adaptive algorithms.